.Pharmacolibrary.Drugs.ATC.C.C10AX11 .Pharmacolibrary.Drugs.ATC.C.C10AX11| name: | Mipomersen |
| ATC code: | C10AX11 | route: | subcutaneous |
| n-compartments | 2 |
Mipomersen is an antisense oligonucleotide inhibitor of apolipoprotein B-100 synthesis, used for the treatment of homozygous familial hypercholesterolemia to reduce LDL cholesterol. It was approved by the FDA but is not currently marketed in many regions, including the US, due to safety concerns.
Pharmacokinetic parameters reported in adult patients with homozygous familial hypercholesterolemia after subcutaneous administration.
Patel, N, & Hegele, RA (2010). Mipomersen as a potential adjunctive therapy for hypercholesterolemia. Expert opinion on pharmacotherapy 11(15) 2569–2572. DOI:10.1517/14656566.2010.512006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20707601
Li, Z, et al., & von Moltke, LL (2014). Pharmacokinetics, safety and tolerability of mipomersen in healthy Japanese volunteers and comparison with Western subjects. International journal of clinical pharmacology and therapeutics 52(4) 314–320. DOI:10.5414/CP201975 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24548981
Li, Z, et al., & Boltje, I (2014). Lack of clinical pharmacodynamic and pharmacokinetic drug-drug interactions between warfarin and the antisense oligonucleotide mipomersen. Journal of cardiovascular pharmacology 64(2) 164–171. DOI:10.1097/FJC.0000000000000101 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24691275